Industry News (Joint Venture)

Small Molecule Compounds Treat Chronic Anemias

Published in Blood Weekly, April 14th, 1997

Oncogene Science, Inc., Uniondale, New York, announced signing of a collaborative research and license agreement with Hoechst Marion Roussel to develop orally active, small molecule inducers of erythropoietin (EPO) gene expression for the treatment of anemia due to chronic renal failure and anemia associated with chemotherapy for AIDS and cancer.

Both Oncogene Science and Hoechst Marion Roussel contribute medicinal chemistry and preclinical optimization teams and Hoechst Marion Roussel are responsible for the clinical development of drug candidates emerging from the program.

The program focuses on the preclinical and clinical development of lead...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry